Cargando…

Bladder metastasis from type 2 papillary renal cell carcinoma: A case report

Renal cell carcinoma (RCC) is a common urinary tumor that may be pathologically divided into different subtypes: clear cell RCC, papillary RCC (PRCC) and chromophobe RCC. The most common organs of RCC metastasis are the lung, liver and bones, while bladder metastasis is rare. The treatment for PRCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Qinsong, Luo, Shuhang, Chen, Linze, Chen, Lingwu, Chen, Junxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193377/
https://www.ncbi.nlm.nih.gov/pubmed/37216161
http://dx.doi.org/10.3892/ol.2023.13856
_version_ 1785043824020553728
author Zeng, Qinsong
Luo, Shuhang
Chen, Linze
Chen, Lingwu
Chen, Junxing
author_facet Zeng, Qinsong
Luo, Shuhang
Chen, Linze
Chen, Lingwu
Chen, Junxing
author_sort Zeng, Qinsong
collection PubMed
description Renal cell carcinoma (RCC) is a common urinary tumor that may be pathologically divided into different subtypes: clear cell RCC, papillary RCC (PRCC) and chromophobe RCC. The most common organs of RCC metastasis are the lung, liver and bones, while bladder metastasis is rare. The treatment for PRCC metastasis is also a problem due to limited clinical data. Therefore, every single case of PRCC metastasis may significantly contribute to establishing a standard treatment protocol. The present study reported on a patient who suffered from repetitive bladder PRCC metastasis with 1.5 years of follow-up. A 54-year-old male patient was diagnosed with left renal pelvic carcinoma in March 2020 and underwent a laparoscopic radical nephroureterectomy of the left kidney. The postoperative histological examination revealed that the tumor was consistent with a type 2 PRCC. Bladder metastasis was discovered three months after the surgery and transurethral resection of the bladder tumor (TURBT) was performed to eliminate the tumor in the bladder. Only three months after the initial TURBT, bladder metastasis was detected again, combined with lung metastasis. The patient refused to undergo radical cystectomy. Therefore, a second TURBT was arranged and targeted drugs were administered. However, both bladder and lung metastases were insensitive to the treatment strategy applied, although immunotherapy was subsequently added. The patient died in October 2021 due to respiratory failure and cachexia. The report aims to provide the whole treatment progress and lessons learned from this case, which is relatively rare.
format Online
Article
Text
id pubmed-10193377
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-101933772023-05-19 Bladder metastasis from type 2 papillary renal cell carcinoma: A case report Zeng, Qinsong Luo, Shuhang Chen, Linze Chen, Lingwu Chen, Junxing Oncol Lett Case Report Renal cell carcinoma (RCC) is a common urinary tumor that may be pathologically divided into different subtypes: clear cell RCC, papillary RCC (PRCC) and chromophobe RCC. The most common organs of RCC metastasis are the lung, liver and bones, while bladder metastasis is rare. The treatment for PRCC metastasis is also a problem due to limited clinical data. Therefore, every single case of PRCC metastasis may significantly contribute to establishing a standard treatment protocol. The present study reported on a patient who suffered from repetitive bladder PRCC metastasis with 1.5 years of follow-up. A 54-year-old male patient was diagnosed with left renal pelvic carcinoma in March 2020 and underwent a laparoscopic radical nephroureterectomy of the left kidney. The postoperative histological examination revealed that the tumor was consistent with a type 2 PRCC. Bladder metastasis was discovered three months after the surgery and transurethral resection of the bladder tumor (TURBT) was performed to eliminate the tumor in the bladder. Only three months after the initial TURBT, bladder metastasis was detected again, combined with lung metastasis. The patient refused to undergo radical cystectomy. Therefore, a second TURBT was arranged and targeted drugs were administered. However, both bladder and lung metastases were insensitive to the treatment strategy applied, although immunotherapy was subsequently added. The patient died in October 2021 due to respiratory failure and cachexia. The report aims to provide the whole treatment progress and lessons learned from this case, which is relatively rare. D.A. Spandidos 2023-05-05 /pmc/articles/PMC10193377/ /pubmed/37216161 http://dx.doi.org/10.3892/ol.2023.13856 Text en Copyright: © Zeng et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Case Report
Zeng, Qinsong
Luo, Shuhang
Chen, Linze
Chen, Lingwu
Chen, Junxing
Bladder metastasis from type 2 papillary renal cell carcinoma: A case report
title Bladder metastasis from type 2 papillary renal cell carcinoma: A case report
title_full Bladder metastasis from type 2 papillary renal cell carcinoma: A case report
title_fullStr Bladder metastasis from type 2 papillary renal cell carcinoma: A case report
title_full_unstemmed Bladder metastasis from type 2 papillary renal cell carcinoma: A case report
title_short Bladder metastasis from type 2 papillary renal cell carcinoma: A case report
title_sort bladder metastasis from type 2 papillary renal cell carcinoma: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193377/
https://www.ncbi.nlm.nih.gov/pubmed/37216161
http://dx.doi.org/10.3892/ol.2023.13856
work_keys_str_mv AT zengqinsong bladdermetastasisfromtype2papillaryrenalcellcarcinomaacasereport
AT luoshuhang bladdermetastasisfromtype2papillaryrenalcellcarcinomaacasereport
AT chenlinze bladdermetastasisfromtype2papillaryrenalcellcarcinomaacasereport
AT chenlingwu bladdermetastasisfromtype2papillaryrenalcellcarcinomaacasereport
AT chenjunxing bladdermetastasisfromtype2papillaryrenalcellcarcinomaacasereport